October 21, 2016: Merck announced that upon the recommendation of an independent DMC it has halted a Phase III trial of Keytruda in advanced urothelial cancer because it met its primary endpoint.
October 21, 2016: Stocks can take a leap for a variety of reasons, and in the biotech industry, that is often connected to some catalytic event—positive results in a clinical trial, deal news, or the launch of a drug.
October 21, 2016: U.S. Sen. Bernie Sanders is not done with Ariad. One week ago today on Twitter he decried the company for systematically increasing the price of its leukemia drug, Iclusig, more than 73 percent since the drug’s launch in 2012.
October 21, 2016: Investors certainly appreciate it when share prices jump due to another company’s success or failure. That’s certainly true this morning as shares of Cerecor have spiked more than 21 percent thanks to Alkermes.